bioRxivCancer BiologyPreprint
Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models
Abstract
Programmed death-ligand 1 (PD-L1) expression is a survival mechanism employed by tumours to mediate immune evasion and tumour progression. PD-1/PD-L1-targeted therapies have revolutionised the cancer therapy landscape due to their ability to promote durable anti-tumour immune responses in select patients with advanced cancers. However, some patients are unresponsive, hyper-progressive or develop resistance. Better characterisation of the 3D architecture of solid tumours by utilising 3D cell culture could provide an environment that more closely recapitulates in vivo human tumours for investigating tumour-intrinsic PD-L1 signalling and immunotherapy responses. Here we investigated whether PD-L1 expression by human breast, prostate and colorectal cancer cell lines altered in 3D cell culture models compared to their 2D monolayer counterparts. We found that PD-L1 expression changed in 3D-cultured cancer cells when compared to 2D-cultured cells. Additionally, the expression of immunological markers, PD-1, PD-L2, CD44, DR4, DR5, Fas, and HLA-ABC were assessed in 3D cell culture and compared to their expression in 2D. These markers were also altered in 3D compared to 2D-cultured cells, highlighting the importance of utilising 3D models which may better able the investigation of tumour-intrinsic PD-L1 signalling, responses to PD-1/PD-L1-targeted therapy, and combination therapies.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer
M. Zuazo-Ibarra, H. Arasanz, … D. Escors·bioRxiv·May 22, 2018
- Patient-Derived Three-Dimensional Lung Tumor Models to Evaluate Response to Immunotherapy
Kayla F. Goliwas, Kenneth P. Hough, … Jessy S. Deshane·bioRxiv·May 19, 2025
- Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity
Jinwoo Nah, Amanda Sun, … Chrysothemis C. Brown·bioRxiv·Sep 16, 2026
- PD-L1ATTAC mice reveal the potential of targeting PD-L1 expressing cells in cancer therapy
E. Fueyo-Marcos, C. Fustero-Torre, … M. Murga·bioRxiv·Jul 22, 2022
- Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the PD-L1/PD-1 blockade therapy-resistant tumor
W. Oh, A. M. J. Kim, … S.-O. Lim·bioRxiv·Aug 4, 2023
- Dynamic PD-L1 Regulation Shapes Tumor Immune Escape andResponse to Immunotherapy
Bruce Pell, Aigerim Kalizhanova, … Yang Kuang·CancersPeer-reviewed·Nov 27, 2025